[Future targets in the treatment of type 2 diabetes]

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) and metabolic syndrome present significant clinical challenges.
• Current lifestyle interventions like diet and exercise are often difficult for patients to adhere to.
• Understanding T2DM pathogenesis drives the development of novel therapeutic targets.

Purpose of the Study:

• To review emerging therapeutic strategies for T2DM and metabolic syndrome.
• To explore novel targets including hepatic glucose production, insulin secretion, insulin signaling, and body fat reduction.
• To assess the clinical progress of new drug classes.

Main Methods:

• Review of current research on T2DM pathogenesis and therapeutic targets.
• Analysis of investigational drugs targeting glucose metabolism and insulin action.
• Evaluation of agents stimulating glucose-dependent insulin secretion (e.g., GLP-1 agonists, DPP-IV antagonists).
• Assessment of drugs affecting glucose production (e.g., glucagon antagonists, amylin analogues).
• Examination of agents targeting lipid oxidation and nuclear receptors (e.g., PPAR agonists).

Main Results:

• Glucagon-like-peptide 1 (GLP-1) agonists and dipeptidylpeptidase IV antagonists enhance glucose-dependent insulin secretion and improve hyperglycemia.
• Glucagon antagonists and amylin analogues demonstrate potential in reducing glucagon-dependent glucose production.
• Peroxisome proliferator activator receptor (PPAR) gamma agonists and dual PPAR alpha/gamma agonists are under development for metabolic benefits.
• Modulation of lipid oxidation shows limited glucose-lowering effects and potential side effects.
• Direct insulin signal transduction modulation remains largely in experimental stages.

Conclusions:

• Novel therapeutic approaches targeting specific pathways in T2DM pathogenesis are advancing.
• Agents like GLP-1 agonists and PPAR agonists show promise in clinical trials.
• Further research is needed to optimize insulin signaling modulation and address limitations of current therapies.